Novo Nordisk chair and six board members to step down
Moves follow disagreement with Danish drugmaker’s majority shareholder the Novo Nordisk Foundation
Moves follow disagreement with Danish drugmaker’s majority shareholder the Novo Nordisk Foundation
Boardroom shake-up at European drugmaker grants Lars Rebien Sørensen wide-ranging powers
Danish drugmaker expects sales and profit growth at lower end of its guidance this year
Outcome is blow to one of Europe’s largest listed companies
Share slide wipes more than €60bn off value of Danish maker of Ozempic and Wegovy
Danish group loses share in diabetes drugs to rivals, with first-half sales growth easing to 8%
Danish group’s challenges mount despite winning reprieve after Hims & Hers withdraws plan to sell copycat Wegovy pill
